Replay available

Processa Pharmaceuticals, Inc. (PCSA) Q4 2022 Earnings Call

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) Q4 2022 earnings conference call, held 2023-03-30. Replay captured from the company's public earnings webcast.

Thu, March 30, 2023 at 4:30 PMendedReplay
Processa Pharmaceuticals, Inc. (PCSA) Q4 2022 Earnings Call

Hosted by

Featured presenters

Naz Rahman

Analyst, Maxim Group

Dr. David Young

Chief Executive Officer

Francois Brisbois

Analyst, Oppenheimer

Jim Stanker

Chief Financial Officer

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Processa Pharmaceuticals, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.049 -- 00:00:03.472 thank you for holding ladies and gentlemen please continue to hold your conference will 00:00:03.472 -- 00:00:09.158 begin shortly please continue to hold your conference will begin momentarily 00:00:09.158 -- 00:00:11.358 thank you 00:00:29.651 -- 00:00:33.252 Thank you. Thank you. 00:01:00.503 -- 00:01:02.803 you you 00:01:34.448 -- 00:01:39.070 Greetings and welcome to the Processa Pharmaceuticals year-end 2022 earnings call and 00:01:39.070 -- 00:01:43.611 corporate update. At this time, all participants are in a listen-only mode. 00:01:43.611 -- 00:01:47.113 A question and answer session will follow the formal presentation. 00:01:47.113 -- 00:01:49.734 As a reminder, this call is being recorded. 00:01:49.734 -- 00:01:53.895 It is now my pleasure to introduce Jim Stanker, Chief Financial Officer. 00:01:53.895 -- 00:01:54.856 Thank you, sir. 00:01:54.856 -- 00:01:57.096 You may begin. 00:01:57.096 -- 00:02:00.467 Thank you and welcome to Processa's 2022 00:02:00.518 -- 00:02:04.656 year-end results and corporate update conference call. 00:02:04.656 -- 00:02:09.238 Joining me on the call today is our Chief Executive Officer, Dr. 00:02:09.238 -- 00:02:14.961 David Young. Shortly before this call, we filed our year-end Form 10-K. 00:02:14.961 -- 00:02:18.963 I will briefly touch on our published financial results and then turn it over to Dr. 00:02:18.963 -- 00:02:23.085 Young to provide an update on our drug development activities. 00:02:23.085 -- 00:02:26.907 I want to remind everyone that a PowerPoint presentation will accompany Dr. 00:02:26.907 -- 00:02:32.230 Young's prepared remarks. To view the PowerPoint presentation, please go to the Investor 00:02:32.230 -- 00:02:37.362 Relations section on our website or to our earnings p...